A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Summary

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.

Timeline

Start

2022-12-19

Primary completion

2025-02-03

Completion

2025-12-23

Outcome

Met primary endpoint

release “Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).” incyte.com ↗

release “As previously reported, both STOP-HS1 and STOP-HS2 studies met their primary endpoint at each tested dose (45 mg and 75 mg).” incyte.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Povorcitinib	Small molecule	—	Oral

Indications